Professor Iwao Ojima

Distinguished Professor and Director of  ICB&DD 
Arthur C. Cope Scholar

Research Highlights


Visit the Ojima Group home page

 

Biographical Sketch

Name: Iwao Ojima
Title: Distinguished Professor of Chemistry and Director of  ICB&DD 
Arthur C. Cope Scholar

Date & Place of Birth: June 5, l945, Yokohama, Kanagawa, Japan

Education:  

1968 B. S. degree The University of Tokyo
1970 M. S. degree The University of Tokyo
1973 Ph.D. degree The University of Tokyo (Prof. Naoki Inamoto)

 

Appointments:

 l973-l983 Senior Research Fellow and Group Leader, Sagami Institute of Chemical Research
1983 Associate Professor, Department of Chemistry, State University of New York at Stony Brook
1984 Professor, Department of Chemistry, State University of New York at Stony Brook
1989 Professeur invité, Université Claude Bernard Lyon I, Lyon, France
1991 Leading Professor, Department of Chemistry, State University of New York at Stony Brook
1995 Distinguished Professor, Department of Chemistry, State University of New York at Stony Brook
1996 Visiting Professor, The University of Tokyo, Tokyo, Japan
1997 Visiting Professor, The Scripps Research Institute, La Jolla, CA
1997 Professeur invité, Université de Paris XI, BIOCIS, Châtenay-Malabry, France
1997-2003 Chairman, Department of Chemistry, State University of New York at Stony Brook
2003 Director, Institute of Chemical Biology and Drug Discovery, Stony Brook.

 

Awards and Honors:

(Awards)

·  The 25th National Young Investigator Award ("Shimpo Sho"), The Chemical Society of Japan, 1976.

·  Arthur C. Cope Scholar Award, the American Chemical Society, 1994.

·  The 51st Chemical Society of Japan Award (“Nihon Kagaku Kai Sho”) for distinguished achievements, The Chemical Society of Japan, 1999.

·  Emanuel B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the American Chemical Society, 2001.

·  Outstanding Inventor Award, The Research Foundation of the State University of New York, 2002.

·  NYSTAR Faculty Development Award, New York State Office of Science, Technology & Academic Research, 2002.

 

(Other Honors)

·  Fellow, John Simon Guggenheim Memorial Foundation, 1995.

·  Fellow, American Association for the Advancement of Science, 1997.

·  Fellow, New York Academy of Sciences, 2000.

·  American Chemical Society, Medicinal Chemistry Hall of Fame, 2006.

 

 

·  William and Florence Catacosinos Professor in Cancer Research, Stony Brook Foundation, 1994.

·  Leading Professorship, State University of New York at Stony Brook, 1991

·  Distinguished Professorship, State University of New York, 1995

·  He was invited by the Royal Swedish Academy of Sciences to serve as a nominator for the Nobel  prize in chemistry for the years 1990, 1996, 2002.

·  Eli Lilly Lecturer, University of Kansas-Lawrence, 1990.

·  National Science Council Lecturer, Taiwan, 1990.

·  J. Clarence Karcher Lecturer, The University of Oklahoma, 1992.

·  George Lesher Lecturer, Rensselaer Polytechnic Institute, 1995.

·  Boehringer-Ingelheim Distinguished Lecturer, Colorado State University, 1997.

·  Weissberger-Williams Lecturer, Eastman Kodak Co., 1997

·  Dr. H. Martin Friedman University Lecturer, Rutgers, State University of New Jersey, 2001

·  Bristol-Meyers Squibb Distinguished Lecturer, Colorado State University, 2002

·  FMC Discovery Chemistry Lecturer, FMC Corporation, 2003

·  J. Clarence Karcher Lecturer, The University of Oklahoma, 2003

·  Guest Editor, “Drug Resistant Tuberculosis: A Challenge in Chemotherapy”, Curr. Topics Med. Chem., 2006

·  Guest Editor, “Modern Molecular Approaches to Drug Discovery”, Acc. Chem. Res., 2007

·  Negishi-Brown Lecturer, Purdue University, 2007

·  Guest Editor, “Modern Natural Products Chemistry in Drug Discovery”, J. Med. Chem., 2007

 

Professional Activities:

(Advisory Board)

 

1.      Editorial Advisory Board of Journal of Molecular Catalysis (1986-1995)

2.      Editorial Advisory Board of Journal of Organic Chemistry (ACS) (1995-1999)

3.      Editorial Advisory Board of Organometallics (ACS) (1996-1998)

4.      Editorial Advisory Board of Current Topics in Medicinal Chemistry (2002-)

5.      Editorial Advisory Board of Letters in Drug Design & Discovery (2003-)

6.      Editorial Advisory Board of Medicinal Chemistry (2004-)

7.      Editorial Advisory Board of Chemistry Letters (2005-)

8.      Editorial Advisory Board of Anti-Cancer Agents in Medicinal Chemistry (2006-)

9.      Basic Science Advisory Board member, Cancer Institute for Long Island (1999-).

 

(Symposia and Conferences)

 

1.      Chairperson, The Stony Brook Symposium on Taxol and Taxotère, "New Hope for Breast Cancer Chemotherapy" (1993).

2.      Chairperson, Symposium on "Recent Advances in the Chemistry of Taxane and Taxoid Anticancer Agents", 207th American Chemical Society National Meeting, San Diego, March (1994).

3.      Chairperson, Symposium on "Fluoroamino Acids and Peptides in Medicinal Chemistry", 210th American Chemical Society National Meeting, Chicago, August (1995).

4.      Organizer and Chairperson, Symposium on "New Prospects in Anticancer Agents for the 21st Century" 219th American Chemical Society National Meeting, San Francisco, March (2000).

5.      Organizer, Ernest Guenther Award Symposium”, the 219th American Chemical Society National Meeting, San Francisco, March 2000.

6.      Organizer, Ernest Guenther Award Symposium, the 229th American Chemical Society National Meeting, San Diego, March (2005).

7.      Organizer, Symposium on “Drug Resistant Tuberculosis – Challenge in Chemotherapy”, the 229th  American Chemical Society National Meeting, San Diego, March (2005).

8.      Organizer, ACS Award in Organometallic Chemistry Symposium, the 231st American Chemical Society National  Meeting, Atlanta, GA, March (2006).

9.      Editorial Advisory Board of Anti-Cancer Agents in Medicinal Chemistry (2006-)Organizer, “Ernest Guenther Award Symposium, the 233rd American Chemical Society National Meeting, Chicago, IL, March (2007).

10.  Organizer, “Modern Molecular Strategies for Tumor-Targeting Drug Dilivery”, the 234th American Chemical Society National Meeting, Boston, MA, August (2007).

 

(Advisory Committee, Panel Reviewer)

 

1.      Advisory Committee Member, NIH, Medicinal Chemistry (MCHA) Study Section (1988-1992).

2.      Ad Hoc Member, Triennial Oversight Committee, Chemistry Division, NSF (1992).

3.      Panel Reviewer, Basic Energy Science Program, U. S. Department of Energy (1992).

4.      Advisory Committee Member Reserve, NIH (1992-1995).

5.      Panel Reviewer, REU Program, Chemistry Division, NSF (1992).

6.      Panel Reviewer, NSF Postdoctoral Fellowship in Chemistry (1994).

7.      Chemistry and Related Sciences Special Emphasis Panel, NIH, Bioorganic and Natural Product Chemistry (BNP-1) Program (1995).

8.      Special Panel Reviewer, NIH, Medicinal Chemistry (MCHA) Study Section (1995).

9.      Chemistry and Related Sciences Special Emphasis Panel, NIH, Bioorganic and Natural Product Chemistry (BNP-1) Program (1996).

10.  Chemistry and Related Sciences Special Emphasis Panel, NIH, SBIR and STTR Programs (1996).

11.  Panel Reviewer, NSF Small Business Innovation Research (SBIR) Program (1997).

12.  Special Panel Reviewer, NIH, Medicinal Chemistry (MCHA) Study Section (1998).

13.  Special Panel Reviewer, NIH, Medicinal Chemistry (MCHA) Study Section (2001).

14.  Special Panel Reviewer, NIH, Bioorganic and Natural Product Chemistry (BNP) Study Section (2002).

15.  Panel Reviewer, NCI, Basic & Preclinical Subcommittee IRG (2002).

16.  Panel Reviewer, NCI, Basic & Preclinical Subcommittee IRG (2003).

17.  Panel Reviewer, NIH, Drug Discovery & Molecular Pharmacology (DMP) Study Section, Oncological Sciences IRG (2004).

18.  Panel Reviewer, NCI, National Cooperative Drug Discovery Groups for Cancer (NCDDG) IRG (2004).

19.  Special Emphasis Panel Reviewer, NCI, ONC-K Study Section (2005).

20.  Special Emphasis Panel Reviewer, NIH, BCMB-B Study Section (2005).

 

(American Chemical Society)

 

1.      Executive Committee Member, Division of Organic Chemistry, American Chemical Society (1998-2001).

2.      Long Range Planning Committee, Division of Medicinal Chemistry, American Chemical Society (2004-)

 

Consulting:

He has served as a consultant for E. I. du Pont, Eli Lilly, Air Products & Chemicals, Mitsubishi Chem.  Ind., Nippon Steel Corp. Life Science Division, Rhone-Poulenc Rorer, ImmunoGen, Inc., Taiho Pharmaceutical Co., Milliken & Co., Aventis Pharma, OSI Pharmaceuticals, Inc., Ajinomoto Co., Inc. (current), INDENA, SpA (current), Central Glass Co. (current), Mitsubishi Chem. Corp. (current).

 

Memberships

He is a member of American Chemical Society, American Association for the Advancement of Science, American Association for Cancer Research, American Peptide Society, New York Academy of Sciences, Sigma Xi, The Chemical Society of Japan, and The Society of Synthetic Organic Chemistry, Japan.

 

Research Interest and Activities:

His research interests include drug design and discovery (anticancer agents, antibacterial agents, enzyme inhibitors, antithrombotic agents), medicinal chemistry and chemical biology, catalytic asymmetric synthesis, organic synthesis by means of organometallic reagents and catalysts, homogeneous catalysis and organometallic chemistry, peptide and peptidomimetics, b-lactam chemistry, and organofluorine chemistry (fluoroamino acids and peptides, medicinal applications).  He has published more than 360 papers and reviews in leading journals and more than l50 patents and patent applications, edited 6 books, and he has given 84  Plenary and Invited Lectures in international conferences and symposia by October 2007.  SciFinder list more than 650 publications to his credit. He has also given more than 100 invited lectures at universities, research institutes, and industries in the last 5 years (total >440 since his move to Stony Brook in 1983).

Selected Plenary and Invited Lectures In International Meetings Since 2002:

63.  F&F International Seminar on “Prospects in Finechemicals, Pharmaceuticals, and Fluoromaterials”, [M. Harada, Organizer], Tokyo, May 21-22, 2002. “Use of Fluorine in the Medicinal Chemistry and Chemical Biology of Bioactive Compounds”.

64.  International Symposium on Pharmaceuticals and Intermediates [T,-P. Lin, Organizer], Kunshan, China, May 30, 2002.  “Discovery, Development, and Chemical Biology of New Generation Taxane Anticancer Agents”

65.  Gordon Research Conference on Heterocyclic Chemistry [W. Murray, Chairman], New Port, RI, July 7-12 (2002).  “New Cyclizations for the Syntheses of Heterocycles”.

66.   43th  American Society of Pharmacognosy Annual Meeting [Robert P. Borris, Organizer], New Brunswick, NJ, July 27-31 (2002). "Discovery, Development and Chemical Biology of New Generation Taxane Anticancer Agents".

67.  .17th Annual William S. Johnson Symposium in Organic Chemistry [Organizers:  C. Khosla, B. M. Trost, P. A. Wender], Stanford University, Stanford, CA, October 25-26, 2002.  “Chemistry and Chemical Biology of New Generation Taxoid Anticancer Agents”.

68.   The 2003 “Visions in Chemistry” Symposium [T. R. Nieduzak, Chairman], American Chemical Society, North Jersey Section and Avenits, Ratitan, NJ, May 14, 2003. “Chemistry and Chemical Biology of New Generation Taxoid Anticancer Agents”.

69.   Bürgenstock International Symposium on “Fluorine in Life Sciences” [M. Schlosser, Chairman], Bürgenstock, Switzerland, July 6-9, 2003.  “Use of Fluorine in the Medicinal Chemistry and Chemical Biology of Bioactive Compounds”.

70.   Symposium on “Fluorinated Synthons” [V. Soloshonok, V. A. Petrov, Chairpersons], September  7-9, 2003, 226th American Chemical Society National Meeting, New York, NY. “Enantiopure 4-Trifluoromethyl- and 4-Difluoromethyl-1-acyl-beta-lactams as Versatile Intermediates for Fluoroamino Acids and Fluoro-Taxoids”.

71.  13 European Symposium on Organic Chemistry [V. Sunjic, Chairman], Dubrovnik, Croatia, September 10-15, 2003.    “Discovery and Development of New Generation Taxane Anticancer Agents”.

72.  The 19th Pesticide Science Society of Japan Symposium,[T. Niki, Organizer], Yokohama, Japan, November 6-7, 2003.“Synthetic Organic Chemistry at the Biomedical Interface”.

73.  Pharmaceutical Sciences World Congress  (PSWC2004) [Y. Sugiyama, Chairman], Kyoto, Japan, May 29-June 3, 2004.  “Chemistry and chemical biology of taxane anticancer agents”

74.  Ischia Advanced School of Organic Chemistry (IASOC) Conference [R. Caputo, Chairman], September 18-23, 2004. “Synthetic Methods and Applications at the Biomedical Interface"

75.  17th International Symposium on Fluorine Chemistry, Shanghai, China [W.-Y. Huang, Chairman], July 24-29, 2005. “Synthetic Organofluorine Chemistry at the Biomedical Interface”.

76.  ACS Symposium on “Current Frontiers of Fluoroorganic Chemistry” [V. Soloshonok; K. Mikami, Organizers], 230 American Chemical  Society National Meeting, Washington, D. C., August 28 – September 1, 2005. “Organofluorine Chemistry at the Biomedical Interface”.

77.  NATO Science Advanced Study Institute “New Methodologies and Techniques in Organic Chemistry: Sustainable Development in a Secure Environment”, Siena, Italy, October 14-23, 2005. (1) “Asymmetric Catalytic Synthesis with Novel Monodentate Biphenol-Based Monodentate Phosphorus Ligands”; (2) New Cyclizations and Cycloadditions in Organic Synthesis”.

78.  Sagami Chemical Research Center 40th Anniversary Symposium, Tokyo, Japan, October 28, 2005. “Synthetic Organic Chemistry at the Biomedical Interface”.

79.  Pacifichem 2005 Conference, Honolulu, Hawaii, December 15-20, 2005. “Applications of biphenol-based fine-tunable monodentate phoshite and phosphoramidite ligands to catalytic asymmetric reactions”.

80.  The 4th Congress of International Drug Discovery Science and Technology (IDDST-2006), Dalian, China, May 26-June 2, 2006. “Taxane-Based Tumor-Targeting Anticancer Agents”.

81.  7th All-Russian Conference, “Fluorine Chemistry”, Moscow, Russia, June 5-9, 2006. “Organofluorine Chemistry at the Biomedical Interface”.

82.  The 2nd International Conference on Joint Project of Chemical Synthesis Core Research Institutions, “Development of New Synthetic Methods and Creation of Functions”, Kyoto, Japan, August 7, 2007. “Rapid Construction of Fused Heterocycles and Carbocycles by Catalytic Cyclizations and Cycloadditions”.

83.  The 2nd Negishi-Brown Lectures, Purdue University, West Lafayette, IN, August 30, 2007. “Catalytic Asymmetric Transformations with Fine-Tunable Biphenol-Based Monodentate Phosphorus Ligands”.

84.  New England ACS Medicinal Chemistry Symposium, Woburn, MA, September 20, 2007.

85.  First International Conference on Drug Design and Discovery, Dubai, UAE, February 3-6, 2008. [Scheduled]

86.  Swiss Chemical Society, Medicinal Chemistry Division Mini-Symposium on Drug Targeting, Basel, Switzerland, May 29, 2008. [Scheduled]

 

Invited Lectures Since 2002:

 

384.  OSI Pharmaceuticals, Inc., Tarrytown, NY [3/15/02, Dr. A. Casterlhano].

385.  Pfizer, Inc. Groton, CT [4/25/02, Dr. J. Li]

386.  Kyowa Hakko Kogyo. Co., Pharmaceutical Research Institute, Shizuoka, Japan [5/20/02, Dr. J. Shimada]

387.  F&F International Seminar, Tokyo, Japan [5/21-22/02, Prof. T. Sonoda]

388.  Taiho Pharmaceutical Co. Ltd., Hanno Research Center [5/24/02, Dr. K. Noguchi]

389.  Shanghai Institute of Organic Chemistry, Shanghai, China [5/27/02, Prof. F.-L. Qing]

390.  Bristol-Myers Squibb, Wilmington, DE [6/11/02, Dr. E. Yue]

391.  Northeastern Medicinal Chemistry and Pharmacognosy Symposium (NERMCAP XXVII), St. John’s University, Jamaica, NY [6/15/02, Prof. C.-H. Kwon, Prof. V. L. Korlipara, Organizers]

392.  Colorado State University, Fort Collins, CO [10/4/02, Profs. T. Rovis, R. M. Williams, A. I. Meyers]

393.  Central Glass Co., Chemical Research Center, Kawagoe, Japan [10/11/02, Dr. Y. Katsuhara]

394.  The University of Tokyo, Hongo, Tokyo, Japan [10/15/02, Prof. E. Nakamura]

395.  Ajinomoto Co., Inc., Pharmaceutical Research Institute [10/16/02, Dr. T. Tsuji]

396.  Mitsubishi Chemical Corporation, Yokohama Research Center [10/17/02, Drs. M. Takai, H. Urata]

397.  Kitasato Institute, Shirokane, Tokyo, Japan [1/15/03, Dr. M. Omura]

398.  FMC Corporation, Princeton, NJ [2/4/03, Dr. Y. L. Zhang]

399.  “Suri no Tsubasa” Summer Seminar, Hiro, Hawaii, [8/3/03, Dr. H. Hironaka]

400.  Ruder Boskovic Institute, Zagreb, Croatia [9/15/03, Dr. I. Habus]

401.  Mitsubishi Chemical Group Science and Technology Center, Yokohama, Japan [11/4/03. Dr. Urata]

402.  Central Glass, Co., Chemical Research Center, Kawagoe,  Japan [11/5/03, Dr. Kikuchi, Dr. Katsuhara]

403.    Sagami Chemical Research Center, Ayase, Kanagawa, Japan [11/7/03. Dr. K. Hirai]

404.    The University of Tokyo, Hongo, Tokyo, Japan [11/10/03, Prof. E. Nakamura]

405.    Ajinomoto Co., Inc., Pharmaceutical Research Laboratories, Kawasaki, Japan [11/11/03, Dr. E. Nakanishi]

406.    Albany Molecular Research, Albany, NY [11/21/03, Dr. G. Reid, Dr. B. F. Molino]

407.    The University of Oklahoma, Department of Chemistry, Norman, OK [12/11/03, Dr. V. Soloshonok]

408.    Purdue Pharma, L.P., Cranbury, NJ [1/23/04, Dr. S. F. Victory]

409.    Kaneka Chem. Ind., Bioscience Research Institute, Takasago, Hyogo, Japan [5/27/04, Dr. T. Ohashi]

410.    Kyoto University, Department of Synthetic Chemistry and Chemical Biology, Katsura, Kyoto, Japan [5/28/04, Prof. M. Murakami]

411.    Kyoto Pharmaceutical University, Kyoto, Japan [5/29/04, Profs. Y. Hayashi, Y. Kiso]

412.    F&F International Seminar, Tokyo, Japan [6/4/05, Prof. T. Taguchi]

413.    The Kitasato Institute, Shirogane, Tokyo, Japan [6/8/04, Prof. S. Omura]

414.    The Institute of Physical and Chemical Research (RIKEN), Wako, Saitama, Japan [6/11/04, Dr. Y. Ito]

415.    Synta Pharmaceuticals, Inc., Lexington, MA [8/27/04, Dr. C. Borella; Dr. L. Sun]

416.    Università del Piemonte Orientale, Faculty of Pharmacy, Novara, Italy [9/13/04, Prof. G. Appendino]

417.    University of Bologna, Department of Chemistry “G. Ciamician”, Bologna, Italy [9/16/04, Prof. A. Umani-Ronchi; Dr. A. Battaglia]

418.    University of Florence, Department of Organic Chemistry, Florence, Italy [9/27/04, Prof. A. Degl’Innocenti]

419.    University of Pisa, Department of Chemistry and Industrial Chemistry, Pisa, Italy [9/28/04, Prof. P. Salvadori; Dr. L. Di Bari]

420.    Central Glass, Co., Ltd. Ube Research Center, Ube, Yamaguchi, Japan [11/4/04, Dr. Mitsumoto, Dr. Tsurumi]

421.    Ajinomoto Co., Inc., Pharmaceutical Research Institute, Kawasaki, Japan [11/8/04, Dr. M. Shouji]

422.    Mitsubishi Chemical Group, Science and Technology Research Center, Inc., Organic Synthesis and Molecular Catalysis Laboratory, Yokohama, Japan [11/9/04, Dr. H. Urata; Dr. M. Takai]

423.    Mitsubishi Pharma Corp., Discovery Research Laboratory, Yokohama, Japan [11/9/04, Dr. S. Tsuchiya]

424.    The University of Tokyo, School of Pharmaceutical Sciences, Hongo, Bunkyo-ku, Tokyo [11/12/04, Prof. M. Shibasaki]

425.    Luitpold Pharmaceuticals, Inc., Shirley, NY [5/26/05, Dr. E. Hohenschuh]

426.    American Biosciences, Inc. Santa Monica, CA [7/7/05, Dr. N. Desai]

427.    Kitasato Institute of Life Sciences, Graduate School of Infection Control Sciences, Shirogane, Tokyo, Japan [7/19/05, Prof. S. Omura].

428.    WuXi Pharma Tech., Shanghai, China [7/27/05, Dr. S. Chen].

429.    Shanghai Institute of Organic Chemistry, Shanghai, China [7/29/05, Prof. L. Dai]

430.    Pharmaceutical Research Institute, Ajinomoto Co., Inc., Kawasaki, Japan [Dr. M. Shoji, October 31, 2005].

431.    Chemical Research Laboratory, Central Glass Co., Kawagoe, Japan [Dr. K. Tsutumi, Nov. 1, 2005]

432.    Science and Technology Center, Mitsubishi Chemical Group, Yokohama, Japan [Dr. M. Takai, Nov. 7, 2005].

433.    The University of Tokyo, Department of Applied Chemistry, Hongo, Tokyo, Japan [Prof. M. Fujita, Nov. 9, 2005].

434.    Tohoku University, Institute of Multidisciplinary Research for Advanced Materials (IMRAM) [Prof. M, Sodeoka, Nov. 10, 2005].

435.    Honeycomb Worldwide, Inc., Web Seminar [Ms. D. Pe, April 7, 2006].

436.    Schering-Plough Research Institute, Kenilworth, NJ [Dr. S. Venkatraman, June 21, 2006].

437.    Cytokinetics, Inc., South San Francisco, CA [Dr. S. Collibee, September 13, 2006].

438.    Science and Technology Center, Mitsubishi Chemical Group, Yokohama, Japan [Dr. M. Takai, October 31, 2006].

439.    The University of Tokyo, Graduate School of Chemistry, Hongo, Tokyo, Japan [Prof. E. Nakamura, Nov. 1, 2006]

440.    Pharmaceutical Research Institute, Ajinomoto Co., Inc., Kawasaki, Japan [Dr. M. Shoji, November 6, 2006].

441.    Chemical Research Laboratory, Central Glass Co., Kawagoe, Japan [Dr. Y. Takahara, Nov. 9, 2005]

442.    Kitasato Institute and Kitasato University, Shirogane, Tokyo, Japan [Nov. 10, 2006, Prof. S. Omura].

443.    Sepracor Pharmaceuticals, Inc., Marlborogh, MA [Sept. 21, 2007, Dr. L. Shao]

444.    University of Iowa, College of Pharmacy, Division of Medicinal & Natural Products Chemistry, Iowa City, IA [October 2, 2007, Prof. Z. Jin]

In addition to these invited lectures, he and his laboratory members regularly present papers at the American Chemical Society's National Meetings, ACS Winter Fluorine Conference, American Association for Cancer Research (AACR) Annual Meeting, and NCI-EORTC symposium.

 

Selected Publications

Books Edited

1.      Iwao Ojima, "Catalytic Asymmetric Synthesis", VCH Publishers, New York, 1993.

2.      G. I. Georg, T. Chen, I. Ojima, and D. M. Vyas (Eds.),"Taxane Anticancer Agents:  Basic Science and Current Status", ACS Symp. Series 583; American Chemical Society, Washington, D. C., 1995.

3.      I. Ojima, J. McCarthy, and J. T. Welch (Eds.), "Biomedical Frontiers of Fluorine Chemistry", ACS Symp. Series 639; The American Chemical Society, Washington, D. C., 1996.

4.      Iwao Ojima, "Catalytic Asymmetric Synthesis, Second Edition", John Wiley & Sons, New York, 2000.